Eli Lilly cut its sales and profits forecasts for 2019 on Wednesday, blaming costs related to its acquisition of Loxo Oncology and a hit from the recent trial failure for one of its cancer therapy treatments. Shares in the $127bn drugmaker dropped nearly 3 per cent in pre-market trading. Eli a
```
Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```

Support Digital Team

Join BusinessDay whatsapp Channel, to stay up to date

Open In Whatsapp